Published in Medical Letter on the CDC and FDA, January 14th, 2007
MGCD265 targets the c-MET, VEGFR1, VEGFR2, VEGFR3, Tie-2 and Ron receptor tyrosine kinases, which appear to play key roles in tumor development and blood vessel formation (angiogenesis) and tumor survival.
The c-MET target has become one of intense scientific and pharmaceutical interest because of its direct involvement in tumor cell survival and angiogenesis. In addition, there is strong evidence that c-MET levels are associated with poor prognosis in several major solid tumor types.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA